Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Journal of Clinical Oncology · 01.09.2023 · 41 (25) · 4097-4106
DOI: 10.1200/jco.23.00434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.09.2023. Verfasst von Tanios S Bekaii-Saab und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, AZ. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 320-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE Adagrasib, a KRAS G12C inhibitor, has demonstrated clinical activity in patients with KRAS G12C -mutated non–small-cell lung cancer (NSCLC) and colorectal cancer (CRC). KRAS G12C mutations occur rarely in other solid tumor types. We report evaluation of the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRAS G12C mutation. METHODS In this phase II cohort of the KRYSTAL-1 study (ClinicalTrials.gov identifier: NCT03785249 ; phase Ib cohort), we evaluated adagrasib (600 mg orally twice daily) in patients with KRAS G12C -mutated advanced solid tumors (excluding NSCLC and CRC). The primary end point was objective response rate. Secondary end points included duration of response, progression-free survival (PFS), overall survival, and safety. RESULTS As of October 1, 2022, 64 patients with KRAS G12C -mutated solid tumors were enrolled and 63 patients treated (median follow-up, 16.8 months). The median number of prior lines of systemic therapy was 2. Among 57 patients with measurable disease at baseline, objective responses were observed in 20 (35.1%) patients (all partial responses), including 7/21 (33.3%) responses in pancreatic and 5/12 (41.7%) in biliary tract cancers. The median duration of response was 5.3 months (95% CI, 2.8 to 7.3) and median PFS was 7.4 months (95% CI, 5.3 to 8.6). Treatment-related adverse events (TRAEs) of any grade were observed in 96.8% of patients and grade 3-4 in 27.0%; there were no grade 5 TRAEs. TRAEs did not lead to treatment discontinuation in any patients. CONCLUSION Adagrasib demonstrates encouraging clinical activity and is well tolerated in this rare cohort of pretreated patients with KRAS G12C -mutated solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, AZ.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Virginia Cancer Specialists, Fairfax, VA.
- NEXT Oncology, Fairfax, VA.
- US Oncology Research, The Woodlands, TX.
- Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN.
ORCID-Profile: Tanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, Meredith S Pelster, Joshua K Sabari, Navid Hafez, Xiaohong Yan, Hirak Der-Torossian
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Bekaii-Saab, T. S., Yaeger, R., Spira, A. I., Pelster, M. S., Sabari, J. K., Hafez, N., Barve, M., Velastegui, K., Yan, X., Shetty, A., Der-Torossian, H., & Pant, S. (2023). Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation. Journal of Clinical Oncology, 41(25), 4097-4106. https://doi.org/10.1200/jco.23.00434
Vancouver
Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et al. Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation. Journal of Clinical Oncology. 2023;41(25):4097-4106. doi:10.1200/jco.23.00434
BibTeX
@article{BekaiiSaab2023,
author = {Bekaii-Saab, Tanios S and Yaeger, Rona and Spira, Alexander I and Pelster, Meredith S and Sabari, Joshua K and Hafez, Navid and Barve, Minal and Velastegui, Karen and Yan, Xiaohong and Shetty, Aditya and Der-Torossian, Hirak and Pant, Shubham},
title = {Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {25},
pages = {4097--4106},
doi = {10.1200/jco.23.00434}
}
EUVIMED